Russ Cohen

Crypto Market Update: Crypto Bill Clears Senate Panel in Narrow Vote

Here’s a quick recap of the crypto landscape for Friday (January 30) as of 12 noon UTC.

Get the latest insights on Bitcoin, Ether and altcoins, along with a round-up of key cryptocurrencymarket news


Bitcoin and Ether price update

Bitcoin (BTC) was priced at US$83,062.62, down by 4.5 percent over 24 hours.

Bitcoin price performance, January 30, 2025.

Chart via TradingView

Bitcoin price performance, January 30, 2025.

Ether (ETH) was priced at US$2,757.93, down by 5.0 percent over the last 24 hours.

Altcoin price update

  • XRP (XRP) was priced at US$1.77, down by 3.6 percent over 24 hours.
  • Solana (SOL) was trading at US$116.69, down by 3.7 percent over 24 hours.

​Today’s crypto news to know

US Senate panel advances crypto market structure bill

A US Senate committee pushed the crypto market structure bill forward this week, marking the furthest the industry’s flagship policy effort has ever advanced in the chamber.

The legislation cleared the Senate Agriculture Committee on a narrow 12–11 vote, split strictly along party lines after Republicans chose to move ahead without Democratic backing.

Committee Chair John Boozman said months of negotiations had produced “significant progress,” arguing the bill was ready for its next stage despite unresolved disputes. Democrats opposed the markup as a bloc, warning the current text falls short on ethics safeguards and consumer protections.

Despite the progress, Ranking Democrat Amy Klobuchar said negotiations are not over and signaled openness to further talks as the bill advances. One of the sharpest flashpoints remains restrictions on senior government officials profiting from crypto ventures, an issue Democrats want written directly into the law.

The bill must still clear the Senate Banking Committee, where disagreements over stablecoin yield and regulatory scope have already delayed progress. Any final version would also need to reconcile differences with the House-passed bill before heading to the Senate floor.

See also  Exploring Healthcare Stocks Amid the September MarketUnderstanding the September Market and Healthcare Stocks

While the Fed gears up to potentially cut interest rates, September looms as historically turbulent for stocks - an annual battering often termed the 'September Effect.' This trend emerges from a mix of economic moves and the post-summer surge in trading, casting a shadow over the stock market.

The Appeal of Medical Stocks Amidst Volatility

Seeking safety amidst this whirlwind, investors eye medical stocks as a viable shelter from market instability. This attraction intensifies in September as portfolio adjustments spike, driving up trading volumes. The allure lies in rebalancing holdings towards healthcare, a sector anchored in indispensable services, unlike some of its riskier counterparts.

Peering into Promising Healthcare InvestmentsDaVita: A Beacon of Stability

DaVita emerges as a standout in the healthcare arena with robust year-to-date growth of over 40%. Specializing in dialysis services for chronic kidney disease patients, DaVita garners a Zacks Rank #1, reflecting its steadfast trajectory. Trading at 15.1 times forward earnings and under 1 times sales, DaVita's prime valuation is underpinned by an "A" Zacks Style Scores grade for Value.

HCA Healthcare: Weathering the Storm

HCA Healthcare, a stalwart in the non-governmental acute care hospitals domain, mirrors DaVita's resilience with a YTD surge of over 40%. Sporting a Zacks Rank #1, HCA Healthcare basks in a sturdy earnings framework with double-digit EPS growth projections. Its forward earnings multiple of 17.5 times underscores a path of sustained expansion, set to soar by 18% this year and climb another 9% by FY25.

Eli Lilly: Scaling Healthcare Peaks

Lauded for its groundbreaking drug pipeline, Eli Lilly shines bright in combating Type 2 diabetes with pioneering GLP-1 treatments. Carving out a niche in diabetes and obesity therapeutics, Eli Lilly commands optimistic projections for high double-digit growth in both revenue and earnings for FY24 and FY25. The buoyant sentiment surrounding its offerings skyrockets further on the heels of escalating earnings estimate revisions.

The Path Ahead

As September ushers in its customary turbulence, healthcare stocks like DaVita, HCA Healthcare, and Eli Lilly beckon as stalwart pillars of stability amid the market's tempest. Investors eyeing a defensive stance amidst market upheavals may find solace and promise in these resilient healthcare giants.

Navigating Market Volatility with Top Medical Stocks

SEC, CFTC launch joint push to unify crypto oversight

The Securities and Exchange Commission (SEC) and the Commodity Futures Trading Commission (CFTC) recently unveiled a joint initiative aimed at aligning rules for digital asset markets.

Speaking at CFTC headquarters, SEC Chair Paul Atkins said fragmented regulation has created confusion rather than protection for investors.

The effort, dubbed Project Crypto, is intended to reduce uncertainty over whether digital assets fall under securities or commodities law.

CFTC Chair Michael Selig said unclear jurisdiction has pushed innovation offshore, leading to firms exhibiting reluctance in US investment without regulatory clarity.

US Bitcoin, Ether ETFs suffer near-US$1 billion single-day outflow

US-listed spot Bitcoin and Ether ETFs saw nearly US$1 billion pulled in a single session as crypto prices slid and volatility surged.

Data from SoSoValue showed about US$818 million exiting bitcoin ETFs in one day, the largest daily outflow since November, while ether ETFs lost roughly US$156 million.

Bitcoin fell below US$85,000 during US trading before stabilizing, while Ether dropped more than 7 percent on the day. BlackRock’s IBIT led the redemptions, followed by heavy selling in Fidelity and Grayscale products.

Don’t forget to follow us @INN_Technology for real-time news updates!

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

5 Stocks Our Experts Predict Could Double In the Next Year

By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.